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Abstract
CD25+ regulatory T cells develop in the thymus (nTregs), but may also be generated in the periphery upon stimulation of
naive CD4 T cells under appropriate conditions (iTregs). To gain insight into the mechanisms governing iTreg development,
we performed longitudinal transcriptional profiling of CD25+ T cells during their differentiation from uncommitted naive
CD4 T cells. Microarray analysis of mRNA from CD25+ iTregs early after stimulation revealed expression of genes involved in
cell cycle progression and T cell activation, which largely overlapped with genes expressed in CD25+ effector T cells (Teffs)
used as a control. Whereas expression of these genes remained elevated in Teffs, it declined gradually in developing iTregs,
resulting in a more quiescent phenotype in mature iTregs. A similar pattern of kinetics was observed for biological processes
and for intracellular pathways over-represented within the expressed genes. A maximum dichotomy of transcriptional
activity between iTregs and Teffs was reached at late stages of their maturation. Of interest, members of the FoxO and
FoxM1 transcription factor family pathways exhibited a reciprocal expression pattern in iTregs and Teffs, suggesting a role of
these transcription factors in determining T cell fate.
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Introduction
CD25+ regulatory T cells (Tregs) are a specialized subset of
CD4 T cells. Tregs play a crucial role in establishing and
maintaining peripheral self-tolerance and in terminating immune
reactions by suppressing the activity of effector T cells (Teffs) and
other immune cells [1–3]. They are characterized by the
expression of the forkhead box P3 (Foxp3) transcription factor
and constitute 5–10% of the peripheral CD4 T cell pool [4].
Deficiencies in Foxp3 lead to severe systemic autoimmunity, and
compromised development and/or function of Tregs is associated
with the development of autoimmune diseases [5–9]. Moreover,
reconstitution of Tregs ameliorates disease activity in several
animal models of autoimmunity, inflammation, and graft rejection
[10–14], indicating a promising therapeutic potential of Tregs and
consequently the necessity to understand in detail their develop-
ment and function.
Tregs were initially found to be generated during T cell
development in the thymus (natural occurring Tregs; nTregs) [15].
However, it has now become clear that Tregs can also be
generated from naive CD4 T cells in peripheral lymphoid tissues
(induced Tregs; iTregs) and that peripheral Treg development
might represent a significant source of circulating Tregs [16–18].
Prolonged exposure to peripheral antigens or suboptimal costim-
ulation during antigen presentation has been described to initiate
the development of iTregs [19]. Different soluble factors, such as
cytokines, retinoic acid or neuropeptides provide additional
signals, further facilitating Foxp3 upregulation and the generation
of peripheral Tregs [20–22]. We have demonstrated that
suboptimal activation of naive CD25- CD4 T cells in the presence
of IL-4 induces the generation of functionally competent Foxp3+
iTregs [23].
Although Foxp3 induction and Foxp3-orchestrated expression
of a number of Treg-specific molecules, such as CD25, cytotoxic
T-lymphocyte antigen 4 (CTLA4), glucocorticoid-induced tumor
necrosis factor receptor (GITR) and CD127, are thought to play a
central role in Treg differentiation [24–26], a meta-analysis of
Treg-transcriptional signatures strongly suggested the involvement
of additional regulatory elements [27]. To gain insight into the
molecular program of extrathymic Treg development, we
analyzed the global gene expression profile of CD25+ Tregs
generated in vitro from peripheral naive CD25- CD4 T cells in the
presence of autologous feeder cells and IL-4. At early develop-
mental stages (days 3 and 5), iTreg development was characterized
by a highly active gene expression status that was not overtly
different than that of developing Teffs, as most of the genes
expressed at that time represented biological processes and
pathways involved in proliferation and cell cycle progression.
With prolonged development, the transcriptional program of
iTregs diminished steadily, resulting in about three times lower
numbers of genes expressed in iTregs as compared to Teffs at day
10, whereas the gene diversity between the two populations
achieved its maximum. Two pathways of the Fox transcription
factor family, ‘‘FoxO family’’ and ‘‘FoxM1 transcription factors’’,
were identified to be specifically over-represented during the
development in iTregs and Teffs, respectively, and might,
therefore, represent decisive molecular pathways specifying iTreg
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16913development and activation of Teffs, respectively, providing
additional insight into the transcriptional programs potentially
involved in iTreg development.
Materials and Methods
Reagents and Abs
The following mAbs and reagents were used for purification,
stimulation, and staining of human cells: anti-CD16 (3g8FcIII),
anti-CD3 (OKT3), anti-CD8 (OKT8), anti-CD45RO (UCHL-1),
and anti-HLA-DR (L243; American Type Culture Collection,
Manassas, VA); anti-CD19 (Dako Cytomation, Glostrup, Den-
mark); FITC-conjugated anti-CD3, PE-labeled anti-CD4, and
FITC-labeled anti-CD4 (Sigma-Aldrich, Taufkirchen, Germany);
PE-labeled anti-CD25, FITC-labeled anti-CD27, FITC-labeled
anti-CD45RA, and PE-labeled anti-CD45RO (BD Bioscience,
Heidelberg, Germany); polyclonal goat anti-mouse immunoglob-
ulin (Ig) (MP Biomedicals, Solon, OH); sheep red blood cells
(SBRC) (Fiebig-Na ¨hrstofftechnik, Idstein, Germany), fetal calf
serum (FCS), phosphate-buffered saline (PBS) (Life Technologies,
Carlsbad, CA), normal human serum (NHS). Human recombi-
nant IL-4 was obtained from Endogen, Rockford, IL.
Cell purification
Peripheral blood mononuclear cells (PBMC) were obtained
from heparinized venous blood donated by healthy individuals by
centrifugation over a Ficoll-Hypaque gradient (Sigma-Aldrich).
For isolation of T cells, PBMC were incubated with SRBC as
described previously [28]. The rosette-negative cells were used as
T cell-depleted PBMC (feeder cells). The rosette-positive cells were
further purified by negative selection panning with mAbs to CD8,
CD16, CD19, HLA-DR, and CD45RO as described previously
[29]. CD25+ and CD25- CD4 cell populations were isolated from
the naive CD4 T cells using CD25 magnetic microbeads from
Miltenyi Biotec (Bergisch Gladbach, Germany) according to the
manufacturer’s instructions. The homogeneity and purity of all
isolated populations were routinely controlled by flow cytometry.
Typically, $95% of the cells were positive for CD3 and CD4 and
$95% of the isolated naive cells were positive for CD45RA and
negative for CD45RO. Naive CD25- CD4 T cells were $98%
negative for CD25, while CD25+ cells were $90% positive for
CD25. More than 98% of the cells were viable after purification.
The study was approved by the ethics committee of the University
of Erlangen, and all subjects gave their written informed consent.
Flow cytometry
For surface staining, T cells (1610
5/sample) were washed with
PBS containing 2% FCS, incubated with saturating amounts of
directly fluorochrome-labeled mAb against diverse surface mole-
cules for 15 minutes at 4uC, washed, and analyzed by flow
cytometry (Cytomics FC500; Beckman Coulter, Fullerton, CA).
Generation of CD25+ iTregs
All cell cultures were conducted in RPMI 1640 medium
supplemented with penicillin G/streptomycin (50 U/ml), L-
glutamine (2 mM; all from Life Technologies), and 10% NHS at
37uC in a humidified atmosphere containing 5% CO2. CD25+
iTregs were generated in vitro as previously described [23]. Briefly,
purified naive CD25- CD4 T cells were incubated at a
concentration of 1610
6/ml in the presence of 1610
6/ml
irradiated (30 Gy) autologous feeder cells in a final volume of
2 ml in 24-well cell culture plates (Costar, Cambrige, MA) for 3, 5,
7 and 10 days. IL-4 at a final concentration of 6.25 ng/ml was
added to the cultures (Fig. S1A). Control cultures were incubated
without exogenous IL-4 and resulted in the generation of activated
effector T cells. At indicated time points, cells were harvested,
counted, analyzed for surface expression of CD4 and CD25, and
processed for CD25+ and CD25- T cell magnetic isolation.
Proliferation assay
CD25+ and CD25- T cells recovered after a 10-day culture
(50610
3/well) were cultured together (at a 1:1 ratio) or separately
in triplicates for 3 days in 96-well, round-bottom plates (Costar) in
the presence of soluble anti-CD3 mAb (1 mg/ml) and in the
presence of 100610
3 autologous irradiated feeder cells. Incorpo-
ration of [
3H]TdR (1 mCi/well) by proliferating lymphocytes
during the last 16 h of the culture was measured using a liquid
scintillation counter on a 1205 Wallac Betacounter (Wallac/
Pharmacia, Turku, Finnland).
Preparation of total RNA and real time PCR
Total RNA was extracted from freshly isolated or cultured
CD25+ and CD25- T cells at indicated time points using the
RNeasy Minikit (Qiagen, Hilden, Germany) with an additional
DNA digestion step (RNase Free DNase Set; Qiagen). 0.1–1 mgo f
total RNA was transcribed to cDNA for 1 h at 42uC in a total
volume of 20–50 ml containing 16avian myoblastosis virus reverse
transcriptase (AMV RT) buffer (Promega, Mannheim, Germany),
1 mM dNTPs, 100 ng/ml oligo(dT)12–18 (all from GE Healthcare,
Munich, Germany), and 0.25 U/ml AMV RT (Promega). Real
time PCR was performed in duplicate in a final volume of 25 ml
using either 16the Universal PCR Master Mix and 16TaqMan
Gene Expression Assays-on-Demand for Foxp3, FoxO3a, FoxM1
and cyclophilin A (all from Applied Biosystems, Darmstadt,
Germany) or 16Power SYBR Green PCR Master Mix (Applied
Biosystems) and 70.4 nM primer mix for SYBR Green detection
for MAFF, CCR2, PGDS, PMCH and EF1A1 (MWG-Biotech,
Ebersberg, Germany) in the ABI PRISM 7000 Sequence
Detection System (Applied Biosystems). Primers for SYBR Green
detection were designed using the MacVector software (Accelrys,
Cambridge, UK) to amplify fragments spanning exon-exon
junctions of up to 120 bp in length. Forward-reverse primer pairs
for SYBR Green PCR were as follows, respectively: 59-
CCAGCAAAGCTCTAAAGATCAAGC-39 and 59-AGATGCC
GGTTCAGCTCG-39 for MAFF; 59-CGTTGGGGAGAAGTT
CAGAAGC-39 and 59-TTTTTGGAGTGGGGCAATCC-39 for
CCR2; 59-TGGTAACTCTGTAACTTGGGCAGAC-39 and 59-
GGATGGTTGTCTAACAGGTCAGGC-39 for PGDS; 59-GGA
AGGAGAGATTTTGACATGCTC-39 and 59-GATGATGTGG
ACCAACAGGTATCAG-39 for PMCH; 59-GTTGATATGGTT
CCTGGCAAGC-39 and 59-GCCAGCTCCAGCAGCCTTC-39
for EF1A1. The PCR program was as follows: 95uC for 10 min
followed by 40 cycles of 95uC for 10 sec and 60uC for 1 min and
(for SYBR Green detection) 1 cycle of 95uC for 15 sec, 60uC for
30 sec and 95uC for 15 sec. Relative quantification was performed
by calculating the difference in cross-threshold values (DCt) of the
gene of interest and a housekeeping gene, cyclophilin A and/or
EF1A1, according to the formula 2
-DCt. Where indicated, the
relative expression values were normalized to the expression values
in the control condition.
Control of total RNA quality
Total RNA quality was controlled electrophoretically using the
RNA 6000 Pico Assay (Agilent Technologies, Santa Clara, CA)
according to the manufacturer’s instructions. The electrophoretic
RNA separation was performed in an Agilent 2100 Bioanalyzer
and visualized by the 2100 expert software (both from Agilent
Technologies). A successful ladder run resulted in six well-resolved
Transcriptional Program of iTreg Development
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sample consisted of two well-separated ribosomal peaks.
Two-step biotion-labeled cRNA synthesis and microarray
hybridization
100 ng of total RNA were used for synthesis of biotin-labeled
cRNA for microarray hybridization by two cycles of amplification
using the GeneChip Two-Cycle cDNA Synthesis Kit, GeneChip
IVT Labeling Kit (both from Affymetrix, Santa Clara, CA) and
the MEGAscript T7 Kit (Ambion, Austin, TX) according to the
manufacturers’ instructions. 20 mg of biotin-labeled cRNA were
fragmented with 16 fragmentation buffer (Affymetrix) in a final
volume of 40 ml at 94uC for 35 min. The size distribution of
fragmented biotinylated cRNA samples was analyzed electropho-
retically using the RNA 6000 Pico Assay as described above. 15 mg
of fragmented cRNA were used to hybridize on the GeneChip
HG_U133A array (Affymetrix). Hybridization was performed in a
GeneChip Hybridization Oven 640 (Affymetrix) for 16 hours at
45uC before arrays were washed and stained on a GeneChip
Fluidics Station 400 (Affymetrix), and scanned with a GeneChip
Scanner 3000 (Affymetrix).
Microarray analysis
Signal intensities of the probes on the array were imported into
the microarray data analyzing software GeneSpring GX10
(Agilent Technologies) and an absolute detection call for each
probe (present, marginal, or absent) was assigned by a MAS 5
probe summarization algorithm. The whole analysis of the
microarray data was performed using the GeneSpring GX10
software. Baseline transformation to median of all samples was
applied to each probe to normalize signal intensities of each probe
across all samples to its median. Further analysis was performed
with probes that had a present or marginal call in at least one out
of all analyzed samples. Three independent experiments were
performed for microarrays and gene expression was analyzed
between sample groups consisting of three replicates, except a
group of a 10-day Teffs with two replicates. The analysis was
performed in several steps (Fig. S1). First, the probes with signal
intensities not significantly different (p.0.05) between CD25- cells
at either time point and naive CD25- CD4 T cells (day 0) were
determined by the repeated measures one-way analysis of variance
(ANOVA). Here and latter, the Benjamini-Hochberg correction
for p-value calculation was applied to correct for multiple testing.
Probes not regulated in CD25- cells were further analyzed by a
two-way ANOVA between iTregs or Teffs and the respective
CD25- T cell population at all time points followed by Tukey’s
Honestly Significant Difference (TukeyHSD) post hoc test to
identify significantly different probes at each particular time point.
The fold-change analysis was than applied to identify significant
probes at each time point with at least 2-fold differential expression
between means of three experiments in iTregs or Teffs and the
respective CD25- cell population (‘‘iTreg-" and ‘‘Teff-regulated
probes’’, respectively).
iTreg-specific and Teff-specific transcripts were identified within
the iTreg- and Teff-regulated probes, respectively as probes
having a significant (p,0.05) at least 2-fold differential expression
between iTregs and Teffs in each indipendent experiment at
indicated time points as determined by one-way ANOVA followed
by TukeyHSD test and the fold-change analysis. iTreg- and Teff-
specific probes identified at different time points were hierarchi-
cally clustered based on their expression signals in iTregs and Teffs
at the respective time point applying a Euclidean similarity
measure and Complete linkage rule.
The lists of iTreg- and Teff-regulated probes at each time point
were examined for a significant over-representation of biological
processes (p,0.1) and for a significant overlap with human
pathways (p,0.05) by Gene Ontology (GO) analysis on biological
process terms and ‘‘Find Significant Pathway Analysis’’, respec-
tively. Both analyses use a hypergeometric test for a p-value
computation. In case of the GO analysis, a Benjamini-Yekutieli
correction was applied to account for multiple GO term testing.
Over-represented biological processes were graphically visualized
using Graphviz software (http://www.graphviz.org) (Fig. S3). Find
Significant Pathway analysis used immune and cancer signaling
pathways from the Cancer Cell Map (http://cancer.cellmap.org/
cellmap) and BioCyc database (http://biocyc.org) (pre-loaded in
GeneSpring GX10), human pathways from Kyoto Encyclopedia
of Genes and genomes (KEGG; http://www.genome.jp/kegg) and
Nature Pathway Interaction (http://pid.nci.nih.gov) databases
(both imported into GeneSpring GX10). Only pathways with at
least 50% representation on the microarray platform (number of
pathway-related genes on the platform in relation to the total
number of genes in the pathway 6100%) were included into the
analysis. All microarray data are MIAME compliant and have
been deposited in a MIAME compliant database, e.g. NCBI’s
Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.
gov/geo) and are accessible through GEO Series accession
number GSE24634.
Statistical analysis
Chi-square test was calculated by using GraphPad Prism 5.0
software (GraphPad Software, La Jolla, CA). Expression micro-
array data of the candidate genes and the results of real-time PCR
were analyzed by the two-tailed paired Student’s t test. p-values
#0.05 were considered as statistically significant differences.
Results
Induction of CD25+ iTregs by priming with IL-4
To generate CD25+ iTregs, we cultured naive CD4 T cells for
10 days with feeder cells in the presence of IL-4 as previously
described [23]. To control for successful CD25+ iTreg develop-
ment, cells were analyzed during the culture for CD25 surface
expression and for Foxp3 mRNA expression, and at the end of
differentiation (e.g. day 10) for their proliferative and suppressive
capacity. As shown in Figure 1A, increasing numbers of CD25+ T
cells were detected in the differentiating cultures irrespective of the
presence of IL-4. Both CD25+ T cell populations expressed Foxp3
mRNA (Fig. 1B). At day 10, however, only the CD25+ T cells
purified from IL-4-containing cultures were anergic and possessed
a regulatory capacity as they suppressed proliferation of CD25-
cells in response to CD3 stimulation (Fig. 1C). CD25+ T cells
derived in the absence of IL-4 proliferated vigorously in response
to CD3 stimulation, did not inhibit CD25- T cell proliferation
(Fig. 1C), produced high levels of the effector cytokines IFNc and
TNF after restimulation with PMA/ionomycine [23] and thus,
represented activated effector T cells. They were used, therefore,
as a non-iTreg control (CD25+ Teff) throughout the study.
Identification of CD25+ iTreg-specific genes
To analyze the transcriptional program during CD25+ iTreg
development, RNA from developing cells was analyzed at different
time points of culture (day 3, 5, 7 and 10) by microarray analysis
using the Affymetrix GeneChip HG_U133A (Fig. S1A). We
restricted the analysis to those transcripts whose expression was
not significantly altered in CD25- T cells as compared to the
starting population during the entire culture period (Fig. S1B, Step
Transcriptional Program of iTreg Development
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and 1,487 transcripts, respectively) were identified to show a more
than two-fold different expression (two-way ANOVA; p,0.05) in
CD25+ iTregs and in Teffs compared to the appropriate CD25-
cell population in at least one analyzed time point (Fig. S1B, Step
2). Of the CD25+ T cell-regulated probes, 912 and 1,006
(representing 778 and 861 transcripts, respectively) were up-
regulated in CD25+ iTregs and Teffs, respectively, in at least one
time point but not down-regulated at any time point, whereas 646
and 700 probes (576 and 621 transcripts, respectively) were down-
regulated in at least one time point but not up-regulated at any
time point in iTregs and Teffs, respectively.
The pattern of the expression of transcripts regulated in CD25+
T cells during the culture period was different between CD25+
iTregs and Teffs (p,0.0001) (Fig. 2). After a peak at day 5, the
numbers of up- or down-regulated probes decreased steadily
through day 7 to day 10 in CD25+ iTregs but remained at a
similar level at days 7 and 10 in CD25+ Teffs. The number of
regulated probes at day 10 in CD25+ Teffs was almost three times
that of CD25+ iTregs (580 vs 209, respectively; Fig. 2).
By comparing the probes regulated in iTregs and Teffs, two
gene lists could be identified that contained the iTreg- and Teff-
specific probes with an at least two-fold different expression
between the two subsets (Fig. S1C). 93 probes corresponding to 88
transcripts were specifically up- or down-regulated in CD25+
iTregs at least at one time point during the differentiation culture.
In CD25+ Teffs, 142 probes (130 transcripts) were specifically
regulated. The number of the specifically regulated genes within
either CD25+ T cell population gradually increased during
differentiation resulting in a maximum number of genes
distinguishing iTregs and Teffs at day 10 (Fig. 3A). This indicates
that the specific genetic program for iTregs and Teffs, respectively,
became more prominent in mature cells. Hierarchical clustering
visualized distinct gene clusters characterizing both populations at
every analyzed time point (Fig. 3B). For example, two cytokine
clusters (IL-8 and IL-17A; and IL-3, IL-4, IL-9, IFNc and IL-13)
were up-regulated at days 3 and 5 in Teffs but not in iTregs. At
days 5, 7 and 10, a gene cluster consisting of inflammation-related
surface molecules such as the IL-12 receptor b2 chain (IL-12RB2)
and the CC chemokine receptor 2 (CCR2) was highly expressed in
Teffs but not in iTregs. Expression of several representative
transcripts was validated by real time PCR (Fig. S2).
Biological process analysis
To gain insight into the function of the regulated transcripts, we
performed a biological process analysis by use of the Gene
Ontology (GO) database (http://www.geneontology.org) (Fig.
S1C). The over-represented processes in developing iTregs and
Teffs could be grouped into three major categories all of which are
Figure 1. CD25+ iTreg development. Human naive CD4 T cells depleted of CD25+ cells were cultured with autologous irradiated feeder cells for
10 days in the presence or absence of IL-4. (A) At days 3, 5, 7 and 10 cells were analyzed for CD25 expression. (B) CD25+ and CD25- populations were
magnetically sorted at the days indicated. Foxp3 mRNA expression was assessed in both CD25+ and CD25- populations by real-time PCR and its
relative expression was calculated in relation to cyclophilin mRNA. (C) At day 10, the proliferative and suppressive capacities of CD25+ and CD25- cells
in response to CD3 stimulation were assessed by thymidine incorporation. Data are shown as a mean 6 SEM of three independent experiments (A, B)
or as a mean 6 SD of one representative experiment performed in triplicates (C).
doi:10.1371/journal.pone.0016913.g001
Figure 2. Number of regulated transcripts in CD25+ T cells
during 10 days of culture. Bars indicate numbers of probes with at
least two-fold differential expression between CD25+ iTregs or Teffs and
their corresponding CD25- cell population at each analyzed time point.
doi:10.1371/journal.pone.0016913.g002
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PLoS ONE | www.plosone.org 4 February 2011 | Volume 6 | Issue 2 | e16913Figure 3. iTreg and Teff specific transcripts during development. (A) Number of probes specifically expressed in iTregs and Teffs at different
times during differentiation. (B) Hierarchical clustering was performed on 93 iTreg-specific and 142 Teff-specific probes. Red and green colors indicate
high and low levels of expression, respectively. Rows correspond to individual transcripts. Columns reflect results from three individual donors
denoted as 1 to 3. Cytokine clusters are highlighted by blue boxes (IL8 and IL17A at day 3; and IL3, IL4, IL9, IFNG and IL13 at day 5). Black boxes
denote a cluster of inflammation-related surface proteins.
doi:10.1371/journal.pone.0016913.g003
Table 1. Number of significantly over-represented biological processes within different functional categories.
Category iTregs Teffs
day 3 day 5 day 7 day 10 day 3 day 5 day 7 day 10
Cell cycle regulation 22 10 13 0 32 23 29 27
DNA/RNA metabolism 23 18 15 0 26 13 16 11
Cytoskeleton reorganization 1 0 0 0 4 2 3 3
Miscellaneous* 2 4 0 1 0 2 4 0
*Miscellaneous biological processes. iTregs: day 3 - mitochondrion organization (GO:0007005), protein targeting (GO:0006605); day 5 - NLS-bearing substrate import
into nucleus (GO:0006607), regulation of transcriptional preinitiation complex assembly (GO:0045898), negative regulation of transcriptional preinitiation complex
assembly (GO:0017055), gene expression (GO:0010467); day 10 - positive regulation of I-kappaB kinase/NF-kappaB cascade (GO:0043122). Teffs: day 5 - antigen
processing and presentation of peptide antigen via MHC class I (GO:0002474), gene expression (GO:0010467); day 7 - sulfur metabolic process (GO:0006790), cellular
amino acid metabolic process (GO:0006520), sulfur compound biosynthetic process (GO:0044272), glutation biosynthetic process (GO:0006750).
doi:10.1371/journal.pone.0016913.t001
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metabolism and cytoskeleton reorganization (Table 1). This
pattern supports the assumption that T cell differentiation is
dependent on and associated with cell proliferation. The details of
biological processes differed in iTregs and Teffs, however.
Whereas the number of GO terms associated with cell
proliferation decreased in developing iTregs and were absent at
day 10, they remained at a largely steady level in Teffs (Table 1).
This is in line with the phenotype of functionally mature iTregs,
which are hypoproliferative and anergic, and Teffs, which are
vigorously proliferative upon stimulation.
Early during differentiation, some of these processes were
specifically represented in iTregs or in Teffs. The majority of
biological processes were, however, utilized by both cell
populations (Fig. 4, Fig. S3). During differentiation, the number
of overlapping processes decreased, and in mature iTregs and
Teffs active biological processes were mutually exclusive. The
single GO term significantly over-represented in mature iTregs
was ‘‘positive regulation of I-kappaB kinase/NF-kappaB cascade’’
(GO:0043122) comprising IL1 beta (39402_at, Hs.126256), IL1
receptor like1 (207526_s_at,Hs.66), lymphotoxinalpha (206975_at,
Hs.36), tetraspanin 6 (209108_at, Hs.43233), extracellular matrix
protein 1 (209365_s_at, Hs.81071), neurotrophic tyrosine kinase
receptor type 1 (208605_s_at, Hs.406293), receptor-interacting
serin-threonin kinase 2 (209545_s_at, Hs.103755), CASP8 and
FADD like apoptosis regulator (210563_x_at, Hs.390736), and gap
junction protein alpha 1 (201667_at, Hs.74471).
Pathway analysis
As an alternative analysis, we subjected the iTreg- and Teff-
characteristic gene lists to a pathway analysis scanning immune
and cancer pathways pre-loaded in GeneSpring GX10, human
metabolic pathways from the KEGG database and human
pathways from the Nature Pathway Interaction database (Fig.
S1C). Similar to biological processes, early during the differen-
tiation a significant proportion of pathways was utilized by both,
iTregs and Teffs, whereas at day 10 a pathway dichotomy
became obvious (Fig. 5). The number of significantly enriched
pathways identified in iTregs gradually decreased with differen-
tiation (34, 19, 21 and 9 pathways at days 3, 5, 7 and 10,
respectively). In contrast, they remained at relatively high
numbers in developing and mature Teffs (37, 29, 27 and 31
pathways at days 3, 5, 7 and 10, respectively). This pattern
emphasizes once again the quiescent phenotype of mature iTregs
as compared to T effector cells. Consistent with this, a pathway
characteristic for T cell activation, the calcineurin-regulated
NFAT-dependent transcription pathway, was significantly repre-
sented in iTregs only at days 3 and 5, whereas it was active
throughout the culture in Teffs (Fig. 6A). No pathways consisting
exclusively of down-regulated transcripts could be identified in
iTregs suggesting that developing iTregs do not repress a
particular pathway (Table S1).
Further analysis of pathways specifically represented in iTregs
or in Teffs identified a reciprocal pattern of two signaling pathways
of Fox family transcription factors, FoxO and FoxM1 (Fig. 6B).
Figure 4. GO term enrichment analysis of biological processes
in developing iTregs and Teffs. GO term analysis was performed to
identify biological processes significantly over-represented in iTregs and
Teffs. Enriched processes in iTregs (black bars) and Teffs (grey bars) at
different times organized by their significance score (-log10 p value) are
shown. Red and green boxes indicate unique GO terms for iTregs and
Teffs, respectively. Yellow boxes represent GO terms enriched in the
gene lists of both, iTregs and Teffs.
doi:10.1371/journal.pone.0016913.g004
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PLoS ONE | www.plosone.org 7 February 2011 | Volume 6 | Issue 2 | e16913The schematic illustration of FoxO and FoxM1 transcription
factor networks and the expression profile of transcripts regulated
in iTregs and Teffs are shown in Figs. S4 and S5. Analysis of the
expression profile revealed an up-regulation of FoxO3a
(204132_s_at) in iTregs at days 7 and 10, whereas FoxM1
(202580_x_at) was up-regulated in Teffs, resulting in a shift of the
FoxO3a/FoxM1 ratio in mature populations (Fig. 6C). This
divergent expression pattern was confirmed by real-time PCR
analysis in independent experiments (Fig. 6D). These results
suggest a potential decisive role of the Fox transcription factor
family to determine iTreg versus Teff development during T cell
differentiation.
Discussion
In this study, we analyzed the transcriptional program of
developing CD25+ iTregs using DNA microarray technology. By
comparing the iTreg transcriptome profile with the genes
regulated in Teffs at different time points during their develop-
ment we identified genes differentially expressed in iTregs
compared to Teffs cells at early, middle and late stages of their
maturation. Based on these gene programs, biological processes
and cellular pathways overrepresented in developing cells at each
particular time point could be deduced. This analysis revealed an
activated and proliferative phenotype of iTregs at early develop-
mental stages that gradually became transcriptionally quiescent
during later development and at the fully differentiated stage of
maturation. Importantly, mature iTregs demonstrated the highest
transcriptional diversity with activated Teffs. The iTreg and Teff
transcriptome profiling suggested FoxO family and FoxM1
transcription factor pathways as decisive molecular mechanisms
regulating iTreg development and activation of Teffs, respectively.
To our knowledge, this is the first study that analyzed the global
transcriptome profile and molecular program of human iTreg
development at different developmental stages. Different stimuli
have been described that drive iTreg conversion from CD25-
precursors in the periphery in vivo and in vitro, such as
subimmunostimulatory antigen presentation in vivo [30,31], TGFb
[32,33], retinoic acid [34-37], IFNc [38,39] or particular
neuropeptides (reviewed in [22]). However, a systematic analysis
of molecular processes that facilitate iTreg development in the
periphery has not been carried out. We took advantage of a
previously described in vitro cell culture system which allows iTreg
generation from human naive CD4 CD25- T cells over 10 days in
response to suboptimal stimulation with autologous antigen-
presenting cells and IL-4 [23]. CD25+ iTregs generated in this
setting phenotypically and functionally resemble nTregs, as they
express CD25 and Foxp3, are anergic to mitogenic stimulation
and inhibit the proliferation of effector T cells in response to CD3
stimulation [23]. Therefore, analysis of the gene expression profile
of those CD25+ iTregs at different time points was thought to
allow the identification of genes specifically regulated in Tregs
compared to Teffs and provide insight into the mechanisms
underlying Treg cell development in the periphery.
CD25 and the transcription factor Foxp3 are the best described
and mostly utilized markers for CD25+ Tregs [4,40]. Beside CD25
and Foxp3, a large proportion of genes reported as Treg-specific
genes in nTregs and in TGFb-induced iTregs [27,41,42] were
similarly regulated in mature iTregs generated in our system. For
example, IL2RB, CTLA4, ICOS, IL1R1, IL1RL1, LAG3,
CD103, TRAF1, OX40, CD86, LGALS1, TNFRSF9,
TNFRSF1B, MAF, IRF4, SOCS2, KLRG1, DUSP4 were up-
regulated in our analysis (Table S2) and in nTregs and in TGFb-
induced iTregs [27,41,42]. On the other hand, IL7R, NELL2,
CCR7, ID2, IFNG were down-regulated here (Table S2) as they
were in the previous reports. As the HG_U133A microarray
platform does not include probes for GITR, FOLR4, and GRP83,
the expression of these genes could not be analyzed. Nevertheless,
GITR expression was confirmed in IL-4 induced iTregs by surface
staining [23]. A different surface marker, PECAM1, reported to be
specific for nTregs [43], was down-regulated in our iTregs. This
may be related to their induced nature, since only naive nTreg
cells have been shown to express PECAM1 [43].
With respect to cytokine production, Treg cells are deficient in
the production of pro-inflammatory cytokines [2,44]. In our
system, we observed increased IFNG and IL17A gene expression
in Teffs but not in early and late developing iTregs (Fig. 3B).
Another cluster of Th2-characteristic cytokine genes, IL4, IL13,
IL3 and IL9, showed enhanced expression in Teffs but not in
iTregs at day 5 (Fig. 3B), supporting the conclusion of a
compromised ability of maturating and mature Tregs to produce
effector cytokines in contrast to Teffs [2,44]. Moreover, when
comparing mature iTregs and Teffs (day 10), down-regulation of a
number of cytokine genes such as IFNG, IL2, IL1A, IL8 and IL21
was determined in iTregs. The gene expression pattern of Teffs
was at large comparable with published data sets of effector T cells
[27,42] (Table S3). Of interest, Foxp3 was regulated during the
development of Teffs in our system (Fig. 1B). Foxp3 is expressed in
human T cells upon activation without mediating a regulatory
capacity [45]. Our finding, therefore, is not surprising and in line
with previous reports.
A model of early development of different T cell subsets
including effector and regulatory T cells in the periphery has been
proposed that is characterized by an activation-specific overlap-
ping expression pattern [46]. Accordingly, at later stages, Treg
lineage-specific regulatory genes (such as Foxp3) reduce the
spectrum of effector genes in Tregs, thereby defining their
regulatory functions. Indeed, our analysis of genes regulated in
iTregs and in Teffs at different time points revealed a strong
overlap at the beginning of the development with increasing
differences between expression profiles of developing iTregs and
Teffs up to the most pronounced differences between mature
iTregs and Teffs. The increasing numbers of iTreg-specific and
Teff-specific transcripts throughout the culture time from day 3 to
day 10 illustrate this phenomenon (Fig. 3A). These results correlate
with markedly different functional phenotypes of mature iTregs
and activated Teffs [47].
Increasing differences between iTregs and Teffs during
maturation were also obvious when the functional relevance of
the iTreg-regulated and Teff-regulated transcripts was analyzed by
‘‘pGO enrichment and pathway analysis. Similar to transcripts,
biological processes and pathways that were overrepresented in
developing iTregs decreased in numbers from early to late
developmental stages. In Teffs, in contrast, the numbers of
enriched GO terms and pathways remained high during the whole
culture. This suggests a declining cellular activity of iTregs during
Figure 5. Pathway analysis in developing iTregs and Teffs. Pathway analysis was performed to identify biological pathways significantly over-
represented in iTregs and Teffs. Enriched processes in iTregs (black bars) and Teffs (grey bars) at different times organized by their significance score (-
log10 p value) are shown. Red and green boxes indicate unique pathways for iTregs and Teffs, respectively. Yellow boxes represent pathways
enriched in the gene lists of both, iTregs and Teffs.
doi:10.1371/journal.pone.0016913.g005
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The biological processes enriched within maturating iTreg- and
Teff-regulated genes from day 3 to day 7 were common and
predominantly represented processes controlling proliferation and
cell cycle progression. In mature iTregs, however, the transcripts
expressed did not statistically fit the proliferative process construct,
together indicating a vigorous proliferative status of immature
iTregs followed by a decreasing proliferative capacity during
maturation and an anergic phenotype of mature iTregs. In this
regard, a decline of the proliferative capacity of maturating iTregs
in response to anti-CD3 stimulation was observed from day 7 to 14
of the culture (data not shown). Although overrepresented in both
populations, biological processes regulating proliferation reached a
higher significance level in Teffs than in iTregs, indicating less
active proliferation of developing iTregs as compared to Teffs.
This is in line with a previously published report of an inverse
relationship between cell division and Treg conversion, i.e. limited
proliferation is a requirement for effective peripheral Treg
conversion [30].
Foxp3 is a ’’master regulator‘‘ for Treg development [48,49].
Accumulating evidence suggests that Foxp3 functions within a
higher-order regulation network of signaling molecules and
transcription factors during Treg establishment [27]. Deprived
TCR signaling via inhibition of the PI3K/Akt signaling pathway
by rapamycin (mTOR) induces de novo expression of Foxp3 and
Treg-like gene expression profiles [50]. Similarly, Akt has been
identified as a strong repressor of entry into the Treg phenotype in
vitro and in vivo [51]. Notably, the activation of the PI3K/Akt
pathway is impaired in Tregs as indicated by a reduction in Akt
phosphorylation in these cells [52]. However, the molecular links
between impaired PI3K/Akt signaling and subsequent FoxP3
expression are not completely understood. Here, we identified the
‘‘FoxO family signaling’’ pathway as significantly represented in
iTregs during maturation. The expression of FoxO3a, one of the
key transcription factors of the pathway, was increased in iTregs
compared to Teffs during maturation (Fig. 6). Activity of FoxO3a
is directly regulated by Akt, which phosphorylates FoxO3a
resulting in the inactivation of its function by exclusion from the
nucleus [53]. Thus, suboptimal TCR stimulation in combination
with an inhibition of PI3K/Akt signaling might result in FoxO3a
accumulation in the nucleus of iTregs and participate in the
induction of Foxp3 expression [54,55]. Indeed, phosphorylation of
FoxO3a is reduced in Treg cells [52]. Dephosphorylated FoxO3a
regulates, moreover, the transcription of genes promoting cell
cycle arrest [56] that could support its role in restricting the
proliferation of iTregs during their maturation period. Of note, a
key component of TGFb-mediated inhibition of cell proliferation
is a formation of a Smad-FoxO3a complex [57], suggesting a
central role of FoxO signaling in Treg development in the
periphery.
FoxO3a is also known to repress FoxM1 expression and
activation [58,59]. FoxM1 has a critical role in cell proliferation by
regulating various cell cycle regulatory genes [59]. Loss of FoxM1
is associated with mitosis arrest and disrupted mitotic spindle
integrity [60]. In this study, the ‘‘FoxM1 transcription factor
network pathway’’ was significantly represented in developing and
mature Teffs. The representation of this pathway correlates with
their highly proliferative phenotype throughout development. In
contrast, expression of FoxM1 in Tregs declined from early to late
maturation stages, together suggesting an intriguing link between
FoxO3a and FoxM1 transcription factor signaling in determining
the fate of a Treg or Teff.
In conclusion, using microarray analysis of the transcriptional
program of developing iTregs we provide new insight into Treg
development in the periphery. The detailed understanding of
molecules and pathways involved in peripheral Treg differentia-
tion might provide new therapeutic targets for the treatment of
disorders caused by dysregulation of Tregs, such as autoimmune
diseases, chronic infection and graft rejection.
Supporting Information
Figure S1 Microarray gene analysis of iTreg develop-
ment. (A) Schematic drawing of the experimental strategy. iTregs
and Teffs were generated in vitro from naive CD25- CD4 T cells by
stimulation with autologous feeder cells in the presence or absence
of IL-4, respectively. Total RNA was isolated from CD25- CD4 T
cells before culture (day 0) and from purified CD25+ and CD25-
subsets at days 3, 5, 7 and 10 of the cultures and hybridized on
HG_U133A microarray chips. Data sets (n=50) from three
independent experiments with cells from different donors were
subjected to baseline transformation and the probes were filtered
by flags resulting in a gene list of 15,245 probes with a marginal or
present call in at least one of the 50 samples. (B) Strategy of the
statistical analysis. In the first step, one-way ANOVA was
performed to determine those genes that were not regulated in
CD25- cells throughout the culture assuming that the changes in
gene expression in CD25- cells during the culture reflected
unspecific cell culture interference. The second step was designed
as a two-way ANOVA followed by fold-change analysis testing to
identify probes that were at least two-fold up- or down-regulated in
Teffs or iTregs compared to the corresponding CD25- T cells at
each culture time point. (C) Identification of specific genes and
characteristic biological processes and pathways. The gene lists
from Step 2 were further processed by alternative statistical
analyses: step 3A employed one-way ANOVA to identify genes
that were specifically regulated in iTregs and Teffs; step 3B
performed a GO term analysis of biological processes over-
represented in developing iTregs and Teffs; step 3C utilized the
Cancer Cell Map, BioCyc, KEGG and Nature Pathway
Interaction databases to conduct a pathway analysis in developing
iTregs and Teffs.
(TIF)
Figure S2 Real time PCR analysis. Expression of MAFF
(Hs.517617), CCR2 (Hs.644637), PGDS (Hs.128433), and PMCH
(Hs.707990) in developing iTregs and Teffs from gene chip (A) and
from real time PCR analysis (B). Data are shown as mean+SD
from three (A) and eight (B) experiments in relation to the
expression in naive T cells (day 0). * p,0.05.
(TIF)
Figure S3 Hierarchical network organization of the
significantly enriched GO terms. Each box represents one
GO term and the p value of its enrichment. p1 and p2 values
Figure 6. Pathways characteristic for developing iTregs or Teffs. (A, B) Significance score (-log10 p value) of three pathways characteristic for
iTregs or Teffs development, ‘‘calcineurin-regulated NFAT-dependent transcription in lymphocytes’’ (A), ‘‘FoxO family signaling’’ and ‘‘FoxM1
transcription network’’ (B) during the 10 days of culture. Grey bars indicate significance scores in iTregs, white bars in Teffs. (C, D) Relative expression
of the transcription factors FoxO3a and FoxM1 as a ratio of their mRNA expression levels in iTregs to those in Teffs at each respective time point
determined by microarray (C) and by real-time PCR (D). Data are shown as mean 6 SD from three (C) and five (D) experiments. * p,0.05.
doi:10.1371/journal.pone.0016913.g006
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and green boxes indicate unique GO terms for iTregs and Teffs,
respectively. Yellow boxes represent GO terms enriched in the
gene lists of both, iTregs and Teffs.
(TIF)
Figure S4 Network organization of ‘‘FoxO family sig-
naling’’ and ‘‘FoxM1 transcription factor network’’
pathways. Each node represents proteins, small molecules or
protein complexes participating in the pathway. Nodes marked by
black cycles correspond to the transcripts identified by the
microarray as to be regulated in developing iTregs (‘‘FoxO family
signaling’’) or in developing Teffs (‘‘FoxM1 transcription factor
network’’).
(TIF)
Figure S5 FoxO and FoxM1 pathways. Expression of the
specific transcripts from ‘‘FoxO family signaling’’ and from
‘‘FoxM1 transcription factor network’’ pathways determined by
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